TAC-101 inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma
Cancer Letters, ISSN: 0304-3835, Vol: 198, Issue: 2, Page: 169-177
2003
- 5Citations
- 8Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef4
- Captures8
- Readers8
Article Description
The anti-metastatic effect of 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid (TAC-101) was investigated using our established intrahepatic metastasis model. Orthotopic implantation of a fragment of CBO140C12 hepatoma into the liver resulted in the formation of a solitary tumor nodule and its intrahepatic metastasis. Daily oral administration of TAC-101 at a dose of 8 mg/kg resulted in a significant inhibition of intrahepatic metastasis, but did not affect the growth of the tumor at the implanted site. The down-regulation of transcriptional anti-activator protein-1 (AP-1) activity by TAC-101 paralleled the inhibition of cell invasion and migration through the repression of expression of the mRNAs for urokinase-type plasminogen activator (u-PA) and its receptor (u-PAR). These findings suggest that TAC-101 may improve therapeutic efficacy for liver cancer patients to prevent intrahepatic metastasis.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0304383503003069; http://dx.doi.org/10.1016/s0304-3835(03)00306-9; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0142119397&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/12957355; https://linkinghub.elsevier.com/retrieve/pii/S0304383503003069; http://linkinghub.elsevier.com/retrieve/pii/S0304383503003069; http://api.elsevier.com/content/article/PII:S0304-3835(03)00306-9?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0304-3835(03)00306-9?httpAccept=text/plain; http://dx.doi.org/10.1016/s0304-3835%2803%2900306-9; https://dx.doi.org/10.1016/s0304-3835%2803%2900306-9
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know